CTOs on the Move

Salk Institute

www.salk.edu

 
Unlocking the secrets of life itself is the driving force behind the Salk Institute. Our team of world-class, award-winning scientists pushes the boundaries of knowledge in areas such as neuroscience, cancer research, aging, immunobiology, plant biology, computational biology, and more. Founded by Jonas Salk, developer of the first safe and effective polio vaccine, the Institute is an independent, nonprofit research organization and architectural landmark: small by choice, intimate by nature, and fearless in the face of any challenge.
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.salk.edu
  • 10010 North Torrey Pines Road
    La Jolla, CA USA 92037
  • Phone: 858.453.4100

Executives

Name Title Contact Details
Michael Austin
Director of Information Technology Profile
Jerry Sheehan
Chief Information Officer Profile

Funding

Salk Institute raised $25M on 11/21/2016
Salk Institute raised $14.3M on 10/23/2019

Similar Companies

arizonia infectious disease society

arizonia infectious disease society is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aphios Corp

Aphios Corp is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Q Therapeutics

Q Therapeutics is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Werewolf Therapeutics

Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body`s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors. We are continuing preclinical studies for both WTX-124 and WTX-330 and expect to advance each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor.

Advanced Biotech

Advanced Biotech is a Cobourg, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.